Minerva Neurosciences (NERV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
CEO welcomed attendees, introduced board members, management, and independent auditors, and outlined meeting conduct and access to proxy materials.
Polls were opened for voting on all matters, and attendees were informed about the process for submitting questions.
Board and executive committee updates
Two Class III directors, Dr. David Kupfer and Jan van Heek, were elected to serve until the 2029 annual meeting.
Shareholder proposals
Six proposals were presented: election of directors, amendments to the certificate of incorporation (exculpation of officers and elimination of exclusive forum), advisory votes on executive compensation and its frequency, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Minerva Neurosciences
- Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027.NERV
Jefferies Global Healthcare Conference 20264 Jun 2026 - Roluperidone advances as the first late-stage therapy for negative symptoms of schizophrenia.NERV
Corporate presentation3 Jun 2026 - Net loss rose to $125.4M on non-cash warrant expenses as Phase 3 roluperidone trial launched.NERV
Q1 20265 May 2026 - Roluperidone shows promise for negative symptoms in schizophrenia, with pivotal trial results due next year.NERV
Stifel 2026 Virtual CNS Forum5 May 2026 - Key votes include director elections, charter changes, and auditor ratification for 2026.NERV
Proxy filing23 Apr 2026 - Six key proposals, including governance and compensation changes, are up for vote at the 2026 meeting.NERV
Proxy filing23 Apr 2026 - Six key proposals, including director elections and charter amendments, headline the 2026 annual meeting.NERV
Proxy filing10 Apr 2026 - Registering up to $200M in securities to fund CNS drug development and corporate growth.NERV
Registration Filing11 Mar 2026 - 2025 net loss driven by non-cash charges; Phase 3 trial for roluperidone set for Q2 2026.NERV
Q4 202511 Mar 2026